It was a pleasure to meet with Patrick Vermersch (University of Lille, Lille, France) to discuss the use of tolebrutinib in patients with progressive multiple sclerosis.
The abstract entitled: ‘BTK Inhibitor Tolebrutinib in Patients With Progressive MS: Design of Phase 3 PERSEUS and HERCULES Trials’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.
Questions:
- What is the rationale for the use of tolebrutinib in patients with progressive multiple sclerosis, and what are their potential advantages compared with anti-CD20 therapy?
- What are the aims of the PERSEUS and HERCULES clinical trials?
- How do these trials differ in terms of design and eligibility criteria?
- What will be the primary outcome measures of the studies?
- When are the initial efficacy and safety data expected?
Disclosures: Patrick Vermersch has received honoraria and consulting fees from Biogen, Sanofi-Genzyme, Novartis, Teva, Merck, Roche, Imcyse, AB Science and Celgene; and has received research support from Novartis, Sanofi-Genzyme and Roche.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch
Filmed as a highlight of the EAN Congress, Virtual 2021
